Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd. ( (AU:RHY) ) just unveiled an announcement.
Rhythm Biosciences has entered a strategic partnership with the Australian Genome Research Facility to establish an Australian-based reference laboratory for its geneType genotyping services, enabling local processing of more than 100,000 tests annually. The deal is designed to cut turnaround times and shipping costs, improve service responsiveness, and keep patient samples and data within Australian regulatory frameworks, a key factor for privacy-focused clinicians and institutional buyers. Working alongside its existing US partner Gene by Gene, Rhythm is creating a dual-laboratory, capital‑efficient operating model that builds redundancy, reduces supply chain risk and supports commercial-scale deployment. The AGRF collaboration, expected to begin processing in Q3 FY26, underpins Rhythm’s plans to expand into Southeast Asia in the second half of 2026 by using Australia as a scalable regional processing hub, strengthening its competitiveness for institutional contracts where local processing, data sovereignty and rapid turnaround are critical selection criteria.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.16 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian predictive cancer diagnostics company focused on its geneType™ platform, which uses proprietary Illumina-based genotyping arrays and analysis pipelines to deliver precision health and cancer risk assessment services. The company targets healthcare providers, institutional customers and consumer-initiated channels in Australia and internationally, aiming to offer scalable, high-quality diagnostics with strong data privacy and sovereignty protections.
Average Trading Volume: 540,154
Technical Sentiment Signal: Buy
Current Market Cap: A$50.59M
Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.